Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Jesus G. Berdeja,Amrita Krishnan,Albert Oriol,Niels W.C.J. van de Donk,Paula Rodriguez-Otero,Elham Askari,Maria-Victoria Mateos,Monique C. Minnema,Luciano J. Costa,Raluca Verona,Suzette Girgis,Thomas J Prior,Brandi Hilder,Jeffery Scott Russell,Jenna D. Goldberg,Ajai Chari

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

2021

Jesus G. Berdeja
Amrita Krishnan
Albert Oriol
Niels W.C.J. van de Donk
Paula Rodriguez-Otero
Elham Askari
Maria-Victoria Mateos
Monique C. Minnema
Luciano J. Costa
Raluca Verona
Suzette Girgis
Thomas J Prior
Brandi Hilder
Jeffery Scott Russell
Jenna D. Goldberg
Ajai Chari

8008Background: New immunotherapy targets in MM are needed as patients (pts) continue to relapse. The orphan receptor GPRC5D is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564)...

Keywords:

Orphan receptor
Cancer research
Immunotherapy
first in human
CD3
Medicine
bispecific antibody
G protein-coupled receptor
relapsed refractory
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations